Business Context and Reporting Period
This Form 8-K filing by Cardinal Health, Inc. reports a material definitive agreement entered into on September 30, 2025. The filing concerns a corporate finance transaction involving the company's receivables financing subsidiaries and a syndicate of financial institutions.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or liquidity figures for the reporting period. The document focuses exclusively on the terms of a financing agreement amendment. The only financial metric disclosed is the size of an existing revolving credit facility mentioned in the context of the lenders' other relationships with the company:
- Revolving Credit Facility: $2.0 billion (existing facility where lenders act as syndicate members).
Material Changes
The primary material change reported is the execution of a First Amendment to the Fifth Amended and Restated Receivables Purchase Agreement dated September 1, 2023. Key details include:
- Parties Involved: Cardinal Health Funding, LLC, Cardinal Health 23 Funding, LLC, Griffin Capital, and a syndicate of lenders including Wells Fargo Bank, N.A., The Bank of Nova Scotia, PNC Bank, Bank of America, N.A., Victory Receivables Corporation, and MUFG Bank, LTD.
- Term Extension: The amendment extends the term of the receivables purchase facility to September 28, 2028.
Outlook, Risks, and Management Commentary
The filing notes that the financial institutions involved in the amendment may perform various commercial banking, investment banking, or financial advisory services for the Company in the future for which they receive customary fees and expenses. No specific forward-looking guidance, risk factors, or unusual items are detailed in this specific 8-K text beyond the standard disclosure of lender relationships.
Investor Verification Checklist
- Verify the full text of the First Amendment (Exhibit 10.1) to understand any changes to interest rates, fees, or covenants not explicitly summarized in the 8-K.
- Confirm the impact of the term extension on the company's overall liquidity position and debt maturity profile.
- Review the company's most recent 10-Q or 10-K for the outstanding balance under the receivables purchase facility to assess the scale of the extended commitment.